Lubberman F, Gelderblom H, Hamberg P, et al. A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs? ASCO Annual Meeting 2019, abstract 4564.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker